<DOC>
	<DOC>NCT01217645</DOC>
	<brief_summary>This is a study to assess the distribution, metabolism and excretion of [14C]AZD6765 after a single-dose intravenous administration.</brief_summary>
	<brief_title>Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<criteria>Subjects must have a normal creatinine clearance of â‰¥60 mL/min Subjects who selfidentify their race as Asian History of any clinically significant medical, neurologic or psychiatric disease as judged by the investigator History of symptomatic orthostatic hypotension (ie, postural syncope) Subjects who have received any radiolabelled study drug within 12 months of the Screening Visit. Subjects who are monitored for radioactivity as part of their occupation Subjects who have been exposed to radiation levels above background, (eg, throughXRay examinations) of &gt;5mSv in the last year, &gt;10 mSv over the last 5 years or a cumulative total of &gt;1mSv per year of life.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Major depression disorder</keyword>
</DOC>